[1] Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Consensus recommendations for the clinical application of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2021, 43(4): 405-413. [2] HORTOBAGYI GN, STEMMER SM, BURRIS HA, et al.Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer[J]. Ann Oncol, 2018, 29(7): 1541-1547. [3] TRIPATHY D, IM SA, COLLEONI M, et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915. [4] YAP YG, CAMM AJ.Drug induced QT prolongation and torsades de pointes[J]. Heart, 2003, 89(11): 1363-1372. [5] National Cencer for ADK Monitoring, China. The UK warns that CDK4/6inhibitors can cause interstitial lung disease and pneumonia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(10): 1000. [6] SANTONI M, OCCHIPINTI G, ROMAGNOLI E, et al.Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications[J]. BioDrugs, 2019, 33(6): 613-620. [7] SLAMON DJ, NEVEN P, CHIA S, et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24): 2465-2472. [8] BALL S, SWARUPS, SULTAN A, et al.Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials[J]. Hematol Oncol Stem Cell Ther, 2021, 14(3): 260-262. [9] GROENLAND SL, MARTÍNEZ-CHÁVEZ A, VAN DONGEN MGJ, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib[J]. Clinical Pharmacokinetics, 2020, 59(12): 1501-1520. [10] BRAAL CL, JONGBLOED EM, WILTING SM, et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331. [11] DURAIRAJ C, RUIZ-GARCIA A, GAUTHIER ER, et al.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer[J]. Anticancer Drugs, 2018, 29(3): 271-280. [12] BEACHLER DC, DE LUISE C, JAMAL-ALLIAL A, et al.Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study[J]. BMC Cancer, 2021, 21(1): 97. [13] KNEZHRNČIČ M, IVANOVSKI M, CÖRD, et al. Chia seeds (Salvia Hispanica L.): an overview-phytochemical profile, isolation methods, and application[J]. Molecules, 2019, 25(1): 11. [14] YANG XF, WANG NP, ZENG FD.Effects of active components of traditional Chinese medicine on drug metabolism enzymes[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2002, 27(5): 325-327. [15] HORN JR, HANSTEN PD, CHAN LN.Proposal for a new tool to evaluate drug interaction cases[J]. Ann Pharmacother, 2007, 41(4): 674-680. [16] REN XY, CONG MH.Food and drug interactions: a general review[J]. Electron J Metab Nutr Cancer(肿瘤代谢与营养电子杂志), 2019, 6(1): 7-12. |